AbbVie to invest $195 million in U.S. drug ingredient plant
AbbVie has announced plans to invest $195 million in its manufacturing facility in North Chicago, Illinois, to enhance the production of active pharmaceutical ingredients (API) within the United States.
The move is part of AbbVie’s broader strategy to strengthen domestic manufacturing capabilities, following its earlier pledge to invest more than $10 billion in U.S.-based expansion projects. The company aims to increase output of API, drug products, peptides, and medical devices over the next decade to support future medical breakthroughs.
“This investment underscores our long-term commitment to advancing innovation and ensuring a reliable supply of critical medicines made in America,” said Robert A. Michael, CEO of AbbVie. “Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs.”
Construction of the new API facility in North Chicago is set to begin in fall 2025, with full operations expected by 2027.
AbbVie’s announcement comes amid a broader trend of major pharmaceutical companies bolstering U.S. manufacturing capacity. Industry peers such as Johnson & Johnson and Eli Lilly have also unveiled significant domestic investment plans in recent years. The shift toward onshore production has gained momentum in the wake of former President Donald Trump’s repeated threats to impose tariffs on imported pharmaceuticals.
By reinforcing its manufacturing footprint in the U.S., AbbVie aims to secure supply chain resilience, reduce reliance on foreign-sourced ingredients, and position itself at the forefront of future pharmaceutical innovation.
